Cephalon Drops Patent Suit Vs. Sandoz Over Provigil

Law360, New York (May 3, 2005, 12:00 AM EDT) -- Cephalon, Inc. has dropped its patent infringement suit against Swiss drug maker Sandoz following that drugmaker's decision not to market a generic version of Cephalon's drug Provigil.

According to Cephalon, Sandoz has decided not to challenge Cephalon's patent position on Provigil, a treatment for excessive day-time sleepiness. Instead, Sandoz will wait until 2014 to seek to put out a generic version of the drug, when a patent on one of Provigil's key ingredients is set to expire.

Instead, Sandoz plans to convert its abbreviated new drug...
To view the full article, register now.